Compare SPB & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | COAG |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1994 | 2026 |
| Metric | SPB | COAG |
|---|---|---|
| Price | $88.35 | $38.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $82.40 | N/A |
| AVG Volume (30 Days) | 235.9K | ★ 366.5K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $1.85 | N/A |
| P/E Ratio | $84.38 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $27.47 |
| 52 Week High | $99.06 | $55.42 |
| Indicator | SPB | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 35.66 |
| Support Level | $85.13 | $29.54 |
| Resistance Level | $89.53 | $38.87 |
| Average True Range (ATR) | 1.93 | 3.04 |
| MACD | -0.05 | -0.48 |
| Stochastic Oscillator | 52.48 | 13.71 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.